Literature DB >> 12884094

Prediction of 5-fluorouracil and cisplatin synergism for advanced gastrointestinal cancers using a collagen gel droplet embedded culture.

Shigeru Mori1, Katsuyuki Kunieda, Yasuyuki Sugiyama, Shigetoyo Saji.   

Abstract

PURPOSE: The combination effects of 5-fluorouracil (5-FU) and cisplatin (CDDP) are herein reported using a drug sensitivity assay, with a special focus on the induction of apoptosis.
METHODS: The combination effects of 5-FU and CDDP were examined using in vitro chemosensitivity testing by means of the collagen gel droplet embedded culture drug sensitivity test (CD-DST) in MKN45 and GSS cell lines, and primary gastrointestinal cancer cells ob-tained from 40 patients. Apoptosis was assayed using the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate biotin neck end labeling (TUNEL) method.
RESULTS: The combination of 5-FU with CDDP increased the efficacy of 5-FU 1.16-1.35-fold with the GSS cell line and 1.10-2.01-fold with primary gastric and colorectal cancers when the exposure time was 7 days. In primary tumor cells a synergistic action was noted in 15 of 40 (38%) gastric and colorectal cancers. Both 5-FU and CDDP were found to induce apoptosis in GSS and MKN45 cells, and the number of apoptotic cells increased synergistically after the combined treatment in the GSS cases and showed a correlation with the results of CD-DST.
CONCLUSIONS: Our findings suggested that the efficacy of the combined treatment with 5-FU and CDDP can be predicted by the in vitro chemosensitivity test and that a synergistic effect might be associated with the induction of apoptosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12884094     DOI: 10.1007/s00595-003-2569-4

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  6 in total

1.  Chemosensitivity test for 5-fluorouracil and 5-chloro-2, 4-dihydroxypyridine predicts outcome of gastric cancer patients receiving S-1 postoperatively.

Authors:  Kentaro Maejima; Akira Tokunaga; Teruo Kiyama; Hitoshi Kanno; Hideki Bou; Masanori Watanabe; Hideyuki Suzuki; Eiji Uchida
Journal:  Gastric Cancer       Date:  2010-12-03       Impact factor: 7.370

2.  Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer.

Authors:  Michael Hopfner; Andreas P Sutter; Alexander Huether; Viola Baradari; Hans Scherubl
Journal:  World J Gastroenterol       Date:  2006-09-21       Impact factor: 5.742

3.  Clinical potential of an antitumor drug sensitivity test and diffusion-weighted MRI in a patient with a recurrent solid pseudopapillary tumor of the pancreas.

Authors:  Tomoharu Shimizu; Satoshi Murata; Eiji Mekata; Tohru Miyake; Hajime Abe; Yoshimasa Kurumi; Yoshihiro Endo; Ryoji Kushima; Tohru Tani
Journal:  J Gastroenterol       Date:  2007-11-22       Impact factor: 7.527

4.  A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma.

Authors:  Kazuma Kobayashi; Akihito Tsuji; Sojiro Morita; Tadashi Horimi; Tetsuhiko Shirasaka; Takashi Kanematsu
Journal:  BMC Cancer       Date:  2006-05-06       Impact factor: 4.430

5.  Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer.

Authors:  Katsutaka Mitachi; Kyohei Ariake; Hiroki Shima; Satoko Sato; Takayuki Miura; Shimpei Maeda; Masaharu Ishida; Masamichi Mizuma; Hideo Ohtsuka; Takashi Kamei; Kazuhiko Igarashi; Michiaki Unno
Journal:  Sci Rep       Date:  2021-03-22       Impact factor: 4.379

6.  Clinical predictive value of in vitro anticancer drug sensitivity test for the therapeutic effect of adjuvant chemotherapy in patients with stage II-III colorectal cancer.

Authors:  Eiji Mekata; Hiromichi Sonoda; Tomoharu Shimizu; Takeshi Tatsuta; Tomohiro Yamaguchi; Yoshihiro Endo; Tohru Tani
Journal:  Mol Clin Oncol       Date:  2013-04-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.